Cargando…
Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model
Chemo- and radio-therapy suffer from certain well-recognized drawbacks for lymphoma therapy. Passive immunotherapy with monoclonal antibody has improved outcome for patients with CD20(+) B cell lymphoma, but not for T cell lymphoma. Therefore, novel treatment approaches are clearly required for T ce...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Ivyspring International Publisher
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665034/ https://www.ncbi.nlm.nih.gov/pubmed/29158790 http://dx.doi.org/10.7150/jca.20015 |